• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

灵芝酸A改善高脂高胆固醇饮食诱导的小鼠非酒精性脂肪性肝炎(NASH)。

Ganoderic acid A ameliorates non-alcoholic streatohepatitis (NASH) induced by high-fat high-cholesterol diet in mice.

作者信息

Zhu Jing, Ding Jiexia, Li Siying, Jin Jie

机构信息

Department of Infectious Diseases, The Fourth Clinical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China.

Department of Infectious Diseases, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China.

出版信息

Exp Ther Med. 2022 Apr;23(4):308. doi: 10.3892/etm.2022.11237. Epub 2022 Feb 24.

DOI:10.3892/etm.2022.11237
PMID:35340879
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8931630/
Abstract

Non-alcoholic steatohepatitis (NASH) is becoming a huge global health problem. Previous studies have revealed that ganoderic acids have hepatoprotective and hypocholesterolemic effects. In the present study, to evaluate the anti-NASH activity of ganoderic acid A (GAA), male 6-week-old C57BL/6J mice were divided into the following four groups, which were administered different diets: Normal diet (ND group), high-fat high-cholesterol diet (HFHC group), HFHC diet supplemented with 25 mg/kg/day (GAAL group) or 50 mg/kg/day of GAA (GAAH group). After 12 weeks of GAA treatment, histopathological results revealed that compared with that of the HFHC group, GAA significantly inhibited fat accumulation, steatosis, inflammation and fibrosis in the liver. GAA effectively reduced serum aspartate transaminase and alanine transaminase levels compared with the HFHC model. Furthermore, the endoplasmic reticulum (ER) stress-responsive proteins, including glucose-regulated protein 78, phosphorylated (p)-eukaryotic initiation factor-2α and p-JNK, were significantly suppressed by GAA, while ERp57, p-MAPK and p-AKT were significantly increased after GAA treatment. Taken together, it was concluded that GAA could resist HFHC diet-induced NASH. In terms of its underlying mechanism, GAA could improve liver inflammation and fibrosis by inhibiting hepatic oxidative stress and the ER stress response induced by HFHC.

摘要

非酒精性脂肪性肝炎(NASH)正成为一个巨大的全球健康问题。先前的研究表明,灵芝酸具有肝脏保护和降胆固醇作用。在本研究中,为了评估灵芝酸A(GAA)的抗NASH活性,将6周龄雄性C57BL/6J小鼠分为以下四组,给予不同饮食:正常饮食(ND组)、高脂高胆固醇饮食(HFHC组)、补充25mg/kg/天GAA的HFHC饮食(GAAL组)或50mg/kg/天GAA的HFHC饮食(GAAH组)。GAA治疗12周后,组织病理学结果显示,与HFHC组相比,GAA显著抑制肝脏中的脂肪堆积、脂肪变性、炎症和纤维化。与HFHC模型相比,GAA有效降低了血清天冬氨酸转氨酶和丙氨酸转氨酶水平。此外,GAA显著抑制了内质网(ER)应激反应蛋白,包括葡萄糖调节蛋白78、磷酸化(p)-真核起始因子-2α和p-JNK,而GAA治疗后ERp57、p-MAPK和p-AKT显著增加。综上所述,得出结论:GAA可以抵抗HFHC饮食诱导的NASH。就其潜在机制而言,GAA可以通过抑制HFHC诱导的肝脏氧化应激和ER应激反应来改善肝脏炎症和纤维化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/a59f7c7a23f4/etm-23-04-11237-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/2036090de3ab/etm-23-04-11237-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/b31110b980f9/etm-23-04-11237-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/b341af190c4e/etm-23-04-11237-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/c8528c2546e8/etm-23-04-11237-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/a59f7c7a23f4/etm-23-04-11237-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/2036090de3ab/etm-23-04-11237-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/b31110b980f9/etm-23-04-11237-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/b341af190c4e/etm-23-04-11237-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/c8528c2546e8/etm-23-04-11237-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6d3/8931630/a59f7c7a23f4/etm-23-04-11237-g04.jpg

相似文献

1
Ganoderic acid A ameliorates non-alcoholic streatohepatitis (NASH) induced by high-fat high-cholesterol diet in mice.灵芝酸A改善高脂高胆固醇饮食诱导的小鼠非酒精性脂肪性肝炎(NASH)。
Exp Ther Med. 2022 Apr;23(4):308. doi: 10.3892/etm.2022.11237. Epub 2022 Feb 24.
2
Berberine ameliorates non-alcoholic steatohepatitis in ApoE mice.小檗碱改善载脂蛋白E基因敲除小鼠的非酒精性脂肪性肝炎。
Exp Ther Med. 2017 Nov;14(5):4134-4140. doi: 10.3892/etm.2017.5051. Epub 2017 Aug 28.
3
High-trans fatty acid and high-sugar diets can cause mice with non-alcoholic steatohepatitis with liver fibrosis and potential pathogenesis.高反式脂肪酸和高糖饮食可导致患有非酒精性脂肪性肝炎并伴有肝纤维化及潜在发病机制的小鼠。
Nutr Metab (Lond). 2020 May 26;17:40. doi: 10.1186/s12986-020-00462-y. eCollection 2020.
4
Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis.混合谱系激酶3缺陷型小鼠可免受高脂肪高碳水化合物饮食诱导的脂肪性肝炎。
Liver Int. 2014 Mar;34(3):427-37. doi: 10.1111/liv.12353. Epub 2013 Nov 20.
5
Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats.瑞舒伐他汀改善大鼠高脂高胆固醇饮食诱导的非酒精性脂肪性肝炎。
Liver Int. 2013 Feb;33(2):301-11. doi: 10.1111/liv.12033.
6
β-Glucan ameliorates nonalcoholic steatohepatitis induced by methionine and choline-deficient diet in mice.β-葡聚糖可改善蛋氨酸和胆碱缺乏饮食诱导的小鼠非酒精性脂肪性肝炎。
J Food Biochem. 2020 Oct;44(10):e13408. doi: 10.1111/jfbc.13408. Epub 2020 Jul 26.
7
Intestinal absorption and hepatic elimination of drugs in high-fat high-cholesterol diet-induced non-alcoholic steatohepatitis rats: exemplified by simvastatin.高脂高胆固醇饮食诱导的非酒精性脂肪性肝炎大鼠中药物的肠道吸收与肝脏消除:以辛伐他汀为例
Br J Pharmacol. 2021 Feb;178(3):582-599. doi: 10.1111/bph.15298. Epub 2020 Nov 20.
8
Vertical Sleeve Gastrectomy Attenuates the Progression of Non-Alcoholic Steatohepatitis in Mice on a High-Fat High-Cholesterol Diet.胃袖状切除术可减轻高脂高胆固醇饮食诱导的非酒精性脂肪性肝炎小鼠的病情进展。
Obes Surg. 2019 Aug;29(8):2420-2429. doi: 10.1007/s11695-019-03860-1.
9
Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity.咖啡因和表没食子儿茶素没食子酸酯可缓解高反式脂肪酸和高碳水化合物饮食诱导的小鼠非酒精性脂肪性肝炎:共性与特异性
Front Nutr. 2021 Nov 22;8:784354. doi: 10.3389/fnut.2021.784354. eCollection 2021.
10
Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.膳食晚期糖基化终产物会加重非酒精性脂肪性肝病。
World J Gastroenterol. 2016 Sep 21;22(35):8026-40. doi: 10.3748/wjg.v22.i35.8026.

引用本文的文献

1
Adipocyte-specific deletion of gp130 prevents ketogenic diet-induced hepatic steatosis.脂肪细胞特异性缺失gp130可预防生酮饮食诱导的肝脂肪变性。
Hepatol Commun. 2025 Aug 26;9(9). doi: 10.1097/HC9.0000000000000782. eCollection 2025 Sep 1.
2
Research Progress on the Biological Activity of Ganoderic Acids in over the Last Five Years.近五年灵芝酸生物活性的研究进展
Life (Basel). 2024 Oct 21;14(10):1339. doi: 10.3390/life14101339.
3
Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances.

本文引用的文献

1
Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH.在高脂肪-胆固醇-糖饮食诱导的 NASH 模型中,miR-155 缺陷小鼠的脂肪变性、炎症小体上调和纤维化减轻。
Lab Invest. 2021 Dec;101(12):1540-1549. doi: 10.1038/s41374-021-00626-1. Epub 2021 Aug 27.
2
The Role of Oxidative Stress in NAFLD-NASH-HCC Transition-Focus on NADPH Oxidases.氧化应激在非酒精性脂肪性肝病-非酒精性脂肪性肝炎-肝细胞癌转变中的作用——聚焦于NADPH氧化酶
Biomedicines. 2021 Jun 17;9(6):687. doi: 10.3390/biomedicines9060687.
3
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.
肠道微生物群对代谢相关脂肪性肝炎和肝细胞癌的影响:途径、诊断机会和治疗进展。
Eur J Med Res. 2024 Oct 5;29(1):485. doi: 10.1186/s40001-024-02072-3.
4
Pharmacology of bioactive compounds from plant extracts for improving non-alcoholic fatty liver disease through endoplasmic reticulum stress modulation: A comprehensive review.通过内质网应激调节改善非酒精性脂肪性肝病的植物提取物生物活性化合物药理学:综述
Heliyon. 2024 Jan 23;10(3):e25053. doi: 10.1016/j.heliyon.2024.e25053. eCollection 2024 Feb 15.
5
A herb mixture to ameliorate non-alcoholic fatty liver in rats fed a high-fat diet.一种用于改善高脂饮食喂养大鼠非酒精性脂肪肝的草药混合物。
Heliyon. 2023 Aug 2;9(8):e18889. doi: 10.1016/j.heliyon.2023.e18889. eCollection 2023 Aug.
治疗非酒精性脂肪性肝病和 2 型糖尿病的新兴治疗方法。
Nat Rev Endocrinol. 2021 Aug;17(8):484-495. doi: 10.1038/s41574-021-00507-z. Epub 2021 Jun 15.
4
Anti-oxidant, anti-inflammatory and anti-fibrosis effects of ganoderic acid A on carbon tetrachloride induced nephrotoxicity by regulating the Trx/TrxR and JAK/ROCK pathway.赤芝酸 A 通过调节 Trx/TrxR 和 JAK/ROCK 通路对四氯化碳诱导的肾毒性的抗氧化、抗炎和抗纤维化作用。
Chem Biol Interact. 2021 Aug 1;344:109529. doi: 10.1016/j.cbi.2021.109529. Epub 2021 May 23.
5
Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy.氧化应激在非酒精性脂肪性肝病发病机制中的作用:对预防和治疗的启示
Antioxidants (Basel). 2021 Jan 26;10(2):174. doi: 10.3390/antiox10020174.
6
PMCA4 gene expression is regulated by the androgen receptor in the mouse testis during spermatogenesis.PMCA4 基因的表达在精子发生过程中受睾丸中的雄激素受体调控。
Mol Med Rep. 2021 Feb;23(2). doi: 10.3892/mmr.2020.11791. Epub 2020 Dec 23.
7
Lipid Metabolism in Regulation of Macrophage Functions.脂质代谢在调节巨噬细胞功能中的作用。
Trends Cell Biol. 2020 Dec;30(12):979-989. doi: 10.1016/j.tcb.2020.09.006. Epub 2020 Oct 6.
8
Ganoderic acid A attenuates high-fat-diet-induced liver injury in rats by regulating the lipid oxidation and liver inflammation.灵芝酸 A 通过调节脂质氧化和肝脏炎症减轻高脂饮食诱导的大鼠肝损伤。
Arch Pharm Res. 2020 Jul;43(7):744-754. doi: 10.1007/s12272-020-01256-9. Epub 2020 Jul 26.
9
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.肠道病毒组特征与非酒精性脂肪性肝病严重程度相关。
Gastroenterology. 2020 Nov;159(5):1839-1852. doi: 10.1053/j.gastro.2020.07.005. Epub 2020 Jul 9.
10
Nonalcoholic Steatohepatitis: A Review.非酒精性脂肪性肝炎:综述。
JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298.